• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PolyTherics and Antitope become Abzena

PolyTherics and Antitope become Abzena

May 28, 2014
CenterWatch Staff

CRO PolyTherics has changed its name to Abzena. The new company was created to provide a strong group identity across its two wholly owned subsidiaries, PolyTherics and Antitope, following their combination in July 2013.

PolyTherics' operations will move from London to the Babraham Research Campus in Cambridge, the current site of Antitope's operations, and therefore Abzena's headquarters and major operations will be positioned in a cluster for biopharmaceutical innovation. It also will grow its operations on the Warwick University Science Park, where it maintains a presence following the acquisition of Warwick Effect Polymers by PolyTherics in January 2012.

John Burt, CEO of Abzena, said, "We believe there is a real opportunity for the company to capitalize on an increasing need for high-quality outsourced early stage R&D capabilities and for Abzena to become a leading provider within this global industry. In PolyTherics and Antitope we have well established, respected brands and a broad range of complementary services and technologies. Our new company and identity will allow us to better communicate our full strengths and meet the significant demand we have seen from existing and new customers and partners."

Abzena's services and proprietary technologies are aimed at helping partners identify or create better biopharmaceutical product candidates to advance toward and into clinical development. These services and technologies include immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, manufacturing cell line development, bioconjugation technologies for antibody drug conjugate development and novel polymers for enhancing the therapeutic properties of biopharmaceutical products.

Matthew Baker, chief scientific officer of Abzena and founder of Antitope, said, "While there will be no day-to-day changes for our existing customers and partners, we believe a new, combined identity provides a strong platform for further growth."

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing